Techno Trends
Worldwide advancements and breakthroughs in pharmaceutical products and technology are thoroughly covered by Techno Trends. You may stay up to date with all the most recent pharmaceutical developments (product news and technological trends) taking place throughout the world.
New Xolair® Treats Severe Chronic Rhinosinusitis with Nasal Polyps
Novartis has discovered a new Xolair® indication for the treatment of severe Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) for adults. Xolair® (omalizumab), is the first discovered treatment option for CRSwNP which specifically targets and blocks the growth...
A Novel Oral Therapy Discovered to Treat Adult Patients with Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
Blueprint Medicines Corporation has developed GAVRETO™, an innovative treatment option for adult patients diagnosed with metastatic Rearranged during Transfection (RET) fusion-positive Non-small Cell Lung Cancer (NSCLC)....
Novel Therapy, Toripalimab, Developed to Treat Nasopharyngeal Carcinoma
Toripalimab, a novel therapy has been discovered for the treatment of nasopharyngeal carcinoma by Junshi Biosciences. Toripalimab, the first anti-PD-1 monoclonal antibody developed for the treatment of Nasopharyngeal carcinoma...
Plinabulin Developed to Prevent Chemotherapy-Induced Neutropenia
BeyondSpring Inc develops breakthrough therapy Plinabulin, for chemotherapy-induced neutropenia indication for patients with cancer. Plinabulin is a first-in-class differentiated immune and stem cell modulator....
Kesimpta® (ofatumumab), The First Self Administrated B-cell Therapy Developed
Novartis develops the first and only self administered B-cell therapy, Kesimpta®, for the treatment of relapsing Multiple sclerosis (MS). Kesimpta® becomes the first new B-cell therapy, which can be self-administered once in a month at home by means of Sensoready® autoinjector pen....
GSK Introduces a New Anti-BCMA (B-cell maturation antigen) Therapy, BLENREP
GlaxoSmithKline plc, introduces BLENREP a first-in-class anti-BCMA (B-cell maturation antigen) therapy for the treatment of adult patients with relapsed or refractory multiple myeloma who have undergone at least four prior therapies including an anti-CD38 monoclonal antibody...
AXS-12 Novel Therapy Discovered for the Treatment of Narcolepsy
Axsome Therapeutics, Inc discovered AXS-12 novel therapy for the treatment of cataplexy in patients with narcolepsy. AXS-12 is an oral, highly selective and potent norepinephrine reuptake inhibitor. AXS-12, developed for cataplexy highlights its potential and provides meaningful benefit and substantial improvement for patients over currently available treatment...
Rozlytrek® (entrectinib), The First Tumour-Agnostic Therapy Discovered
Rozlytrek® (entrectinib), the first tumour-agnostic therapy discovered for the treatment of patients with NTRK fusion-positive, locally advanced or metastatic solid tumours in adult...
AstraZeneca Introduces A Breakthrough Therapy-Tagrisso
AstraZeneca introduced Tagrisso (osimertinib), a breakthrough therapy for the adjuvant treatment of patients with early-stage (IB, II and IIIA) Epidermal Growth Factor Receptor-mutated (EGFRm) Non-Small Cell Lung Cancer (NSCLC)....
Merck Discovers Breakthrough Therapy HIF-2α Inhibitor MK-6482
Hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor MK-6482, a novel breakthrough therapy discovered by Merck for the treatment of patients with von Hippel-Lindau (VHL) disease-associated Renal Cell Carcinoma (RCC)....
